Terry Opgenorth, Ph.D., joined KromaTiD in 2010 and serves as the Chairman of the Board of Directors. Dr. Opgenorth previously worked for Abbott Laboratories (now AbbVie) as Divisional Vice President of Metabolic Disease Research, Antiviral (HCV) Research and Target-Lead Discovery Research for Abbott’s Global Pharmaceutical Research and Development division.  He also served as President and CEO of Vidasym for 6 years, a company developing drugs for human chronic kidney disease.  Terry holds a number of current positions, including Vice President and Executive Director of NewCo Lauchpad for CSU Ventures, and CSO/Founder of VetDC, a veterinary oncology company. He also serves on the Board of Directors for Vidasym, UNeMed, MonImmune Therapeutics, and Cetya Therapeutics, and served as Founder/Advisor to Colorado Center for Drug Discovery (C2D2). Dr. Opgenorth holds a B.A. in Biology from Calvin College and M.S. and Ph.D. degrees in Physiology from University of Illinois-Urbana.

Joel S. Bedford, Ph.D., joined KromaTiD as a founder of the company in 2007, chairs the Scientific Advisory Board and is a member of the Board of Directors.  Dr. Bedford is currently a Professor in the Department of Environmental and Radiological Health Sciences at Colorado State Universtiy and holds a joint faculty appointment in the University Graduate Program in Cell and Molecular Biology. His programs have been funded by NIH, DOE and NASA since 1966. He has served as a regular member and Chairperson of the NIH Radiation Study Section, as a Counselor, Associate Editor, and later as President of the Radiation Research Society.  He has received various awards such as the Failla Award and the Excellence in Mentoring Award from the Radiation Research Society.  He has been a regular member of the National Academies’ Board on Radiation Effects Research, and then on the National Academies’ Nuclear and Radiation Studies Board.  He served a 5-year term on the Scientific Council of the Radiation Effects Research Foundation in Hiroshima, Japan, and is a member of the National Council on Radiation Protection and Measurements.  Professor Bedford has authored 140 peer-reviewed articles, including several book chapters, and is an inventor on two patent applications. Professor Bedford received his B.A. degree in Chemistry from the University of Colorado, an M.S. degree in Radiology from the University of Colorado Medical School, and Doctor of Philosophy Degree in Radiobiology from Oxford University.

Nicholas A. Saccomano, PhD, joined the KromaTiD board in 2016. He has served as Chief Scientific Officer of Array BioPharma (Boulder, CO) since May 2014. Dr. Saccomano is a seasoned leader with 30 years of experience in pharmaceutical and biotechnology research and development, with expertise in discovery research, clinical development, portfolio strategy, technology and clinical candidate licensing, and scientific partnering. Dr. Saccomano previously was CTO at SomaLogic, Inc. and before that CSO at Bend Research Inc. Prior to Bend Research, held positions of increasing responsibility at Pfizer, Inc., including Senior VP in R&D and VP of Discovery Technology, where he managed and developed enabling technologies used broadly across the drug discovery pipeline. During his tenure, he also directed medicinal sciences, drug discovery and strategic alliances. Dr. Saccomano obtained his Ph.D. in chemistry from Columbia University.

Ginny Orndorff joined the KromaTiD board in 2015. She is the Executive Director of the Colorado Institute for Drug, Device, and Diagnostic Development (CID4) and acting CEO of SixOne Solutions, LLC, and Claudin Technologies. Ginny co-founded Evolutionary Genomics of Longmont, CO and was its CEO for 10 years, continuing today on its board of directors. Prior to that, she was CEO of GenoPlex of Denver, CO; Director of Technology/Business Development for NeXstar of Boulder, CO; and Director of Biotechnology Programs at the Colorado Advanced Technology Institute. She has a B.A. in Biology from the University of California Santa Cruz, an M.A. in Microbiology from California State University San Jose, and an M.B.A from Loyola College.

Christopher Tompkins Ph.D., President and General Manager

View Bio »